Results 101 to 110 of about 13,960 (212)

Contemporary Concise Review 2025: Asthma

open access: yesRespirology, Volume 31, Issue 7, Page 693-701, July 2026.
ABSTRACT Asthma research in 2025 further advanced a multidimensional view of asthma, integrating disease trajectory, exacerbation risk, structural airway changes, comorbidities, and treatment responsiveness. In mild asthma, studies published in 2025 further reinforced the importance of anti‐inflammatory reliever strategies over SABA‐only treatment by ...
Jun Miyata, Koichi Fukunaga
wiley   +1 more source

Exhaled nitric oxide in diagnosis and management of respiratory diseases

open access: yesAnnals of Thoracic Medicine, 2009
The analysis of biomarkers in exhaled breath constituents has recently become of great interest in the diagnosis, treatment and monitoring of many respiratory conditions. Of particular interest is the measurement of fractional exhaled nitric oxide (FENO)
Abba Abdullah
doaj  

Development of Ultrasound Microbubbles and Phase Shift Microbubbles in Theranostics

open access: yesWIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 4, July/August 2026.
Microbubbles have been originally designed for diagnostic applications. Over the years, microbubbles and phase shift microbubbles have been further developed for therapeutic indications. ABSTRACT Ultrasound is widely used for diagnostic imaging and therapy.
Emmanuelle J. Meuillet, Evan C. Unger
wiley   +1 more source

Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U‐BIOPRED Cohort

open access: yesAllergy, Volume 81, Issue 7, Page 2366-2380, July 2026.
No stable features were identified as associated with asthma symptom control in transcriptomics or sputum proteomics. Higher TWEAKR/TNFRSF12A and MBL/MBP‐C serum levels increased the odds of uncontrolled symptoms, while higher MK08/MAPK8 and CD5L serum levels decreased the odds, after adjustment for clinical variables.
Joana Antão   +294 more
wiley   +1 more source

Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma

open access: yes
Clinical and Translational Allergy, Volume 16, Issue 7, July 2026.
Philipp Suter   +3 more
wiley   +1 more source

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1173-1184, July 2026.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger   +11 more
wiley   +1 more source

Evaluation of a nitrous oxide mobile destruction unit to reduce occupational exposure in a burns department

open access: yes
Anaesthesia, Volume 81, Issue 7, Page 1010-1011, July 2026.
Christelle Machon   +4 more
wiley   +1 more source

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab

open access: yes
British Journal of Haematology, Volume 209, Issue 1, Page 335-339, July 2026.
Isabel C. Vallecillo‐Viejo   +12 more
wiley   +1 more source

Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?

open access: yes
Clinical &Experimental Allergy, Volume 56, Issue 7, Page 791-794, July 2026.
Philipp Suter   +3 more
wiley   +1 more source

Estimating nasal nitric oxide from measured fractional exhaled nitric oxide and nasal fractional exhaled nitric oxide. [PDF]

open access: yesJ Thorac Dis
Abo M   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy